Tarus Therapeutics

Dr. John Stagg, a world-leader in the adenosine pathway, joins Scientific Advisory Board of Tarus Therapeutics, Inc.

Tarus Therapeutics receives clearance from the FDA to initiate clinical trial of TT-4 (A2BR antagonist) in cancer patients

Tarus Therapeutics seeks to initiate clinical trial of TT-4 (A2BR antagonist) in cancer patients

Tarus Therapeutics receives clearance from the FDA to initiate clinical trial of TT-10 (A2AR antagonist) in cancer patients

Tarus Therapeutics seeks to initiate clinical trial of TT-10 (A2AR antagonist) in cancer patients

Tarus Therapeutics Strengthens its Board of Directors with Appointment of Paolo Pucci

Tarus Therapeutics Expands R&D Team with Appointment of Brian Schwartz, M.D. as Interim Chief Medical Officer and Head of the Scientific Advisory Board

Tarus Therapeutics Strengthens Board of Directors with the Appointment of Preeminent Life Sciences Industry Leaders

Tarus Therapeutics, Inc., acquires license to Adenosine Receptor Antagonist Platform from Impetis Biosciences, Ltd.